{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:44:24Z","timestamp":1791834264561,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jcf.2023.01.015","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T22:26:40Z","timestamp":1675808800000},"page":"427-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7529-9196","authenticated-orcid":false,"given":"Meliksah","family":"Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Rentfrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle M.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8859-4231","authenticated-orcid":false,"given":"Mark E.","family":"Wylam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2023.01.015_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International committee on mental health in cystic fibrosis: cystic fibrosis foundation and european cystic fibrosis society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.015_bib0002","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.7861\/fhj.2020-0205","article-title":"The impact of COVID-19 shielding on the wellbeing, mental health and treatment adherence of adults with cystic fibrosis","volume":"8","author":"Westcott","year":"2021","journal-title":"Future Healthc J"},{"issue":"32","key":"10.1016\/j.jcf.2023.01.015_bib0003","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.15585\/mmwr.mm6932a1","article-title":"Mental health, substance use, and suicidal ideation during the COVID-19 pandemic - United States, June 24-30, 2020","volume":"69","author":"Czeisler","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2023.01.015_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcf.2021.08.027","article-title":"Impact of COVID-19 on mental health: effects on screening, care delivery, and people with cystic fibrosis","volume":"20","author":"Smith","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.01.015_bib0005","unstructured":"Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report. 2020 [cited 2022 June 14]; Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"10.1016\/j.jcf.2023.01.015_bib0006","unstructured":"FDA. FDA approves new breakthrough therapy for cystic fibrosis. 2019 [cited 2022 June 14]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-breakthrough-therapy-cystic-fibrosis."},{"issue":"1","key":"10.1016\/j.jcf.2023.01.015_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010023","article-title":"Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: a Systematic Review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.01.015_bib0008","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1054-139X(01)00333-0","article-title":"The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients","volume":"30","author":"Johnson","year":"2002","journal-title":"J Adolesc Health"},{"issue":"12","key":"10.1016\/j.jcf.2023.01.015_bib0009","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","article-title":"Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain","volume":"57","author":"Guo","year":"2009","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jcf.2023.01.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"9590","key":"10.1016\/j.jcf.2023.01.015_bib0011","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the World Health Surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcf.2023.01.015_bib0012","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCP.0b013e3283121cf1","article-title":"Prevalence and impact of depression in cystic fibrosis","volume":"14","author":"Quittner","year":"2008","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.015_bib0013","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1378\/chest.06-2474","article-title":"The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis","volume":"132","author":"Riekert","year":"2007","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.jcf.2023.01.015_bib0014","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOP.0b013e3282ef480a","article-title":"Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator","volume":"19","author":"Smith","year":"2007","journal-title":"Curr Opin Pediatr"},{"issue":"12","key":"10.1016\/j.jcf.2023.01.015_bib0015","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/ppul.22990","article-title":"Depression, illness severity, and healthcare utilization in cystic fibrosis","volume":"49","author":"Snell","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.01.015_bib0016","unstructured":"Cystic Fibrosis Foundation Patient Registry 2019 Annual Data Report. 2019 [cited 2022 June 14]; Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2019-Patient-Registry-Annual-Data-Report.pdf."},{"issue":"2","key":"10.1016\/j.jcf.2023.01.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-053486","article-title":"Suicide Risk in Adolescents During the COVID-19 Pandemic","volume":"149","author":"Lantos","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcf.2023.01.015_bib0018","unstructured":"Organization, W.H. Mental Health and COVID-19: early evidence of the pandemic's impact: scientific brief. 2022 [cited 2022 June 14]; Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1."},{"key":"10.1016\/j.jcf.2023.01.015_bib0019","unstructured":"Brunier, A. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide: wake-up call to all countries to step up mental health services and support, in World Health Organization News. 2022 [cited 2022 November 21]; Available from: https:\/\/www.who.int\/news\/item\/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide."},{"key":"10.1016\/j.jcf.2023.01.015_bib0020","article-title":"The impact of COVID-19 lockdown on child and adolescent mental health: systematic review","author":"Panchal","year":"2021","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jcf.2023.01.015_bib0021","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.jcf.2023.01.015_bib0022","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor \/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2023.01.015_bib0023","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1002\/ppul.26116","article-title":"Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis","volume":"57","author":"Lyman","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.jcf.2023.01.015_bib0024","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.01.015_bib0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12890-022-01825-2","article-title":"Lived experiences of individuals with cystic fibrosis on CFTR-modulators","volume":"22","author":"Page","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jcf.2023.01.015_bib0026","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S1569-1993(21)01721-5","article-title":"Mental health implications of genetic modulator therapy in CF: depression and anxiety screening for pediatric patients prescribed elexacaftor\/tezacaftor\/ivactor during the COVID-19 pandemic","author":"Vance","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:53Z","timestamp":1761601733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1569199323000231"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suicide attempts in adolescents with cystic fibrosis on Elexacaftor\/Tezacaftor\/Ivacaftor therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}